<?xml version='1.0' encoding='utf-8'?>
<document id="24432037"><sentence text="Hemodynamic effect of avanafil and glyceryl trinitrate coadministration."><entity charOffset="22-30" id="DDI-PubMed.24432037.s1.e0" text="avanafil" /><entity charOffset="35-54" id="DDI-PubMed.24432037.s1.e1" text="glyceryl trinitrate" /><pair ddi="false" e1="DDI-PubMed.24432037.s1.e0" e2="DDI-PubMed.24432037.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s1.e0" e2="DDI-PubMed.24432037.s1.e1" /></sentence><sentence text="A Phase I, double-blind, randomized, crossover study in healthy males (N=106) was conducted between March 21, 2004, and May 17, 2004, to determine the magnitude and duration of the hemodynamic interaction of avanafil (a phosphodiesterase type-5 inhibitor for treating males with erectile dysfunction) when coadministered with glyceryl trinitrate (NTG) compared with sildenafil and placebo"><entity charOffset="208-216" id="DDI-PubMed.24432037.s2.e0" text="avanafil" /><entity charOffset="326-345" id="DDI-PubMed.24432037.s2.e1" text="glyceryl trinitrate" /><entity charOffset="347-350" id="DDI-PubMed.24432037.s2.e2" text="NTG" /><entity charOffset="366-376" id="DDI-PubMed.24432037.s2.e3" text="sildenafil" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e0" e2="DDI-PubMed.24432037.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e0" e2="DDI-PubMed.24432037.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e0" e2="DDI-PubMed.24432037.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e0" e2="DDI-PubMed.24432037.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e1" e2="DDI-PubMed.24432037.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e1" e2="DDI-PubMed.24432037.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e1" e2="DDI-PubMed.24432037.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e2" e2="DDI-PubMed.24432037.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s2.e2" e2="DDI-PubMed.24432037.s2.e3" /></sentence><sentence text=" Subjects received avanafil (200 mg), sildenafil (100 mg), and placebo (on separate days) via the oral route followed by NTG (0"><entity charOffset="19-27" id="DDI-PubMed.24432037.s3.e0" text="avanafil" /><entity charOffset="38-48" id="DDI-PubMed.24432037.s3.e1" text="sildenafil" /><entity charOffset="121-124" id="DDI-PubMed.24432037.s3.e2" text="NTG" /><pair ddi="false" e1="DDI-PubMed.24432037.s3.e0" e2="DDI-PubMed.24432037.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s3.e0" e2="DDI-PubMed.24432037.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24432037.s3.e0" e2="DDI-PubMed.24432037.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s3.e1" e2="DDI-PubMed.24432037.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24432037.s3.e1" e2="DDI-PubMed.24432037.s3.e2" /></sentence><sentence text="4 mg) 12, 8, 4, 1, or 0" /><sentence text="5 hours post-dose via the sublingual route" /><sentence text=" Blood pressure (BP) and heart rate (HR) were assessed at defined intervals" /><sentence text=" Throughout the study (after administration of the study drug, and including the period after NTG administration), the effects of avanafil and sildenafil on BP and HR were significantly greatest overall, at the shortest (0"><entity charOffset="130-138" id="DDI-PubMed.24432037.s7.e0" text="avanafil" /><entity charOffset="143-153" id="DDI-PubMed.24432037.s7.e1" text="sildenafil" /><entity charOffset="94-103" id="DDI-PubMed.24432037.s7.e2" text="NTG" /><pair ddi="false" e1="DDI-PubMed.24432037.s7.e2" e2="DDI-PubMed.24432037.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s7.e2" e2="DDI-PubMed.24432037.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s7.e2" e2="DDI-PubMed.24432037.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24432037.s7.e0" e2="DDI-PubMed.24432037.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s7.e0" e2="DDI-PubMed.24432037.s7.e1" /></sentence><sentence text="5-hour) time interval compared with placebo" /><sentence text=" By the 8- and 12-hour time intervals, no significant difference in BP or HR was observed for avanafil (8 and 12 hours) or sildenafil (12 hours) (p&gt;0"><entity charOffset="94-102" id="DDI-PubMed.24432037.s9.e0" text="avanafil" /><entity charOffset="123-133" id="DDI-PubMed.24432037.s9.e1" text="sildenafil" /><pair ddi="false" e1="DDI-PubMed.24432037.s9.e0" e2="DDI-PubMed.24432037.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s9.e0" e2="DDI-PubMed.24432037.s9.e1" /></sentence><sentence text="05, compared with placebo)" /><sentence text=" Compared with avanafil, sildenafil had a significantly greater effect when dosed 0"><entity charOffset="15-23" id="DDI-PubMed.24432037.s11.e0" text="avanafil" /><entity charOffset="25-35" id="DDI-PubMed.24432037.s11.e1" text="sildenafil" /><pair ddi="false" e1="DDI-PubMed.24432037.s11.e0" e2="DDI-PubMed.24432037.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s11.e0" e2="DDI-PubMed.24432037.s11.e1" /></sentence><sentence text="5 hours before NTG on standing HR (p=0"><entity charOffset="15-24" id="DDI-PubMed.24432037.s12.e0" text="NTG" /></sentence><sentence text="05); 1 hour before NTG on standing systolic blood pressure (SBP) (p&lt;0"><entity charOffset="19-21" id="DDI-PubMed.24432037.s13.e0" text="NTG" /></sentence><sentence text="05), sitting SBP (p=0" /><sentence text="01) and standing HR (p&lt;0"><entity charOffset="17-19" id="DDI-PubMed.24432037.s15.e0" text="HR" /></sentence><sentence text="01); and 12 hours before NTG on standing SBP (p=0"><entity charOffset="25-26" id="DDI-PubMed.24432037.s16.e0" text="NTG" /></sentence><sentence text="05)" /><sentence text=" Throughout the study, symptomatic hypotension adverse events occurred in 27%, 29%, and 12%, and clinically significant reductions in standing SBP (≥30 mmHg) occurred in 15%, 29%, and 12% of subjects dosed with avanafil, sildenafil, and placebo, respectively (overall treatment differences: p&lt;0"><entity charOffset="211-219" id="DDI-PubMed.24432037.s18.e0" text="avanafil" /><entity charOffset="221-231" id="DDI-PubMed.24432037.s18.e1" text="sildenafil" /><pair ddi="false" e1="DDI-PubMed.24432037.s18.e0" e2="DDI-PubMed.24432037.s18.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s18.e0" e2="DDI-PubMed.24432037.s18.e1" /></sentence><sentence text="01 and p&lt;0" /><sentence text="05, respectively)" /><sentence text=" These data show that avanafil and sildenafil have no significant effect on BP and HR if administered to healthy males ≥8 hours (avanafil) or ≥12 hours (sildenafil) before a sublingual dose of NTG"><entity charOffset="22-30" id="DDI-PubMed.24432037.s21.e0" text="avanafil" /><entity charOffset="35-45" id="DDI-PubMed.24432037.s21.e1" text="sildenafil" /><entity charOffset="153-163" id="DDI-PubMed.24432037.s21.e2" text="sildenafil" /><entity charOffset="193-202" id="DDI-PubMed.24432037.s21.e3" text="NTG" /><entity charOffset="83-92" id="DDI-PubMed.24432037.s21.e4" text="HR" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e0" e2="DDI-PubMed.24432037.s21.e0" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e0" e2="DDI-PubMed.24432037.s21.e1" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e0" e2="DDI-PubMed.24432037.s21.e4" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e0" e2="DDI-PubMed.24432037.s21.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e0" e2="DDI-PubMed.24432037.s21.e3" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e1" e2="DDI-PubMed.24432037.s21.e1" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e1" e2="DDI-PubMed.24432037.s21.e4" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e1" e2="DDI-PubMed.24432037.s21.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e1" e2="DDI-PubMed.24432037.s21.e3" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e4" e2="DDI-PubMed.24432037.s21.e4" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e4" e2="DDI-PubMed.24432037.s21.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e4" e2="DDI-PubMed.24432037.s21.e3" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e2" e2="DDI-PubMed.24432037.s21.e2" /><pair ddi="false" e1="DDI-PubMed.24432037.s21.e2" e2="DDI-PubMed.24432037.s21.e3" /></sentence><sentence text=" However, results may differ in populations with known vascular disease, especially those using other concurrent pharmacotherapy" /><sentence text=" These findings may be of interest to clinicians who treat patients with erectile dysfunction and who also have a cardiovascular condition" /><sentence text=" Of note, the applicability of these results in such patients may be limited because the enrollment comprised healthy, normal subjects" /><sentence text=" " /></document>